Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
| Brand name | OCTREOTIDE ACETATE |
| Generic name | OCTREOTIDE ACETATE |
| Distributed by / for | TEVA Pharmaceuticals, Parsippany, NJ 07054 |
| NDC | 0480-9262-08 |
| Full product label | Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08. |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | Nationwide in the USA |
| Quantity | 21,930 Cartons |
| Recall initiated | 2026-03-17 |
| Report date | 2026-04-01 |
| Recall completed | — |
| Recall number | D-0406-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗